Modality
Small Molecule
MOA
C5i
Target
BET
Pathway
Lipid Met
Rett
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Sep 2031
Phase 2Current
NCT07779881
900 pts·Rett
2021-04→2031-09·Completed
NCT06928423
1,533 pts·Rett
2022-12→2029-07·Recruiting
2,433 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-07-013.3y awayPh2 Data· Rett
2031-09-045.4y awayPh2 Data· Rett
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2029-07-01 · 3.3y away
Rett
Ph2 Data
2031-09-04 · 5.4y away
Rett
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07779881 | Phase 2 | Rett | Completed | 900 | OS |
| NCT06928423 | Phase 2 | Rett | Recruiting | 1533 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D |